BR

BrightPath Biotherapeutics Co., Ltd.

A clinical-stage biopharma company developing cancer immunotherapies and cell therapies.

4594 | T

Overview

Corporate Details

ISIN(s):
JP3274140007
LEI:
Country:
Japan
Address:
川崎市川崎区殿町三丁目25番22号

Description

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's core technology is its iPS-NKT platform, a novel allogeneic cell therapy that utilizes induced pluripotent stem cells (iPSCs) to produce large, homogeneous quantities of natural killer T (NKT) cells for cancer treatment. This proprietary approach is designed to overcome the natural scarcity of NKT cells, enabling the therapeutic application of their multifaceted anti-tumor effects. In addition to its cell therapy program, the company's development pipeline includes cancer peptide vaccines and immuno-modulating antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-02-09 07:11
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 195.3 KB
2023-11-15 07:27
訂正有価証券届出書(組込方式)
Japanese 183.0 KB
2023-11-14 07:56
有価証券届出書(組込方式)
Japanese 332.0 KB
2023-11-10 07:12
確認書
Japanese 9.1 KB
2023-11-10 07:12
四半期報告書-第21期第2四半期(2023/07/01-2023/09/30)
Japanese 182.5 KB
2023-08-10 08:43
確認書
Japanese 9.1 KB
2023-08-10 08:42
四半期報告書-第21期第1四半期(2023/04/01-2023/06/30)
Japanese 152.2 KB
2023-06-22 07:46
内部統制報告書-第20期(2022/04/01-2023/03/31)
Japanese 23.1 KB
2023-06-22 07:45
確認書
Japanese 8.9 KB
2023-06-22 07:44
有価証券報告書-第20期(2022/04/01-2023/03/31)
Japanese 921.7 KB
2023-02-10 07:41
確認書
Japanese 9.1 KB
2023-02-10 07:39
四半期報告書-第20期第3四半期(2022/10/01-2022/12/31)
Japanese 164.4 KB
2022-12-19 09:07
確認書
Japanese 8.9 KB
2022-12-19 09:06
確認書
Japanese 8.9 KB
2022-12-19 08:27
訂正有価証券報告書-第15期(平成29年4月1日-平成30年3月31日)
Japanese 855.7 KB

Automate Your Workflow. Get a real-time feed of all BrightPath Biotherapeutics Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BrightPath Biotherapeutics Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BrightPath Biotherapeutics Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.